--- title: A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases nct_id: NCT07412691 overall_status: RECRUITING phase: PHASE1 sponsor: BeOne Medicines study_type: INTERVENTIONAL primary_condition: Skin Diseases countries: China canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07412691.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07412691" ct_last_update_post_date: 2026-03-23 last_seen_at: "2026-05-12T06:04:35.585Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases **Official Title:** A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases **NCT ID:** [NCT07412691](https://clinicaltrials.gov/study/NCT07412691) ## Key Facts - **Status:** RECRUITING - **Phase:** PHASE1 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 98 - **Lead Sponsor:** BeOne Medicines - **Conditions:** Skin Diseases - **Start Date:** 2026-03-19 - **Completion Date:** 2028-08-08 - **CT.gov Last Update:** 2026-03-23 ## Brief Summary This is the first-in-human study of BG-A3004. The study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of BG-A3004 after single and multiple doses administered in different dose levels in healthy participants (Part A) and patients with immune-mediated skin diseases (Part B), respectively. Study details include: * The study duration will be approximately 3 years. * The treatment duration will be 1 dose for Part A and 4 doses for Part B. * Safety follow-up period is 168 days after the last dose ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 60 Years - **Sex:** ALL - **Healthy Volunteers:** Yes ``` Inclusion Criteria * Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study. * Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for 180 days after the last dose of study drug. They must also have a negative urine pregnancy test at baseline before first dose of study drug. * Nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for 180 days after the last dose of study drug. Part A (SAD) specific Inclusion criteria * Healthy participants as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring. * must be 18 to 55 years of age, inclusive, at the time of signing the informed consent. * Body mass index (BMI) of 19 to 28 kg/m\^2 Part B (MAD) specific inclusion criteria: * Must be 18 to 60 years of age, inclusive, at the time of signing the informed consent. * Body mass index (BMI) of 18 to 32 kg/m\^2 * Patients with alopecia areata (AA), clinical diagnosis of AA with no other etiology of hair loss. Severity of Alopecia Tool (SALT) ≥ 25 and \< 95 at screening and randomization. * Patients with cutaneous lichen planus (CLP), clinical and histological features of LP with predominant cutaneous involvement. Investigator's Global Assessment (IGA) score of 3 or 4 at screening and randomization. * Patients with nonsegmental vitiligo (NSV), documented clinical diagnosis of NSV for at least 3 months. Facial-Vitiligo Area Scoring Index (F-VASI) ≥ 0.5 and Total body-VASI ≥ 3 at screening and randomization. Exclusion Criteria: * Participants who have a history of severe allergic reactions or hypersensitivity to the active ingredient and excipients of the study drug or drugs of the same class. * Participants who are unable to comply with the requirements of the protocol, unless the written approval of the medical monitor has been obtained before informed consent. * Participants with any malignancy ≤ 5 years before randomization, except for any locally recurring cancer that has been treated curatively * Participants who were administered a live vaccine ≤ 28 days before randomization. * Female participants who are pregnant or are breastfeeding. * History of Tuberculosis or active, latent, or inadequately treated infection * A known history of a primary immunodeficiency or an underlying condition such as HIV infection or splenectomy that predispose the participant to infections. * Known infection with hepatitis B virus \[presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody( HBcAb)\], or presence of hepatitis C virus antibody (HCV Ab) * Have a history of any lymphoproliferative disorder (such as Epstein Barr Virus-related lymphoproliferative disorder, as reported in some participants on other immunosuppressive drugs), history of lymphoma, leukemia, myeloproliferative disorders, multiple myeloma, or signs and symptoms suggestive of current lymphatic disease. * Have an active infection or a history of infection within 6 months before the first dose of study drug that required hospitalization, or parenteral antimicrobial therapy, or have a history of opportunistic infection or a chronic or recurrent infectious disease that, in the opinion of the investigator, makes them unsuitable for this study. * Have or have had symptomatic herpes zoster or herpes simplex within 12 weeks, more than 1 episode of local herpes zoster, or a history (single episode) of disseminated zoster. * Acute disease state (e.g., asthma attack, nausea, vomiting, fever, or diarrhea) within 7 days prior to the first dose of study drug. Part B(MAD) specific exclusion criteria: * Previous use of any Janus Kinase (JAK) inhibitor for any disease indication at any time. * Treatment with systemic immunomodulatory medications within 4 weeks or 5 half-lives (if known), whichever is longer prior to randomization, including immunosuppressants (e.g., methotrexate, cyclosporine, azathioprine); corticosteroids administered orally, intravenously, or intramuscularly; chloroquine derivatives; and oral phosphodiesterase-4 (PDE4) inhibitors (e.g., apremilast). * Phototherapy (UV or laser therapy) or cryotherapy within 4 weeks prior to randomization. * For AA patients, AA that affects more than scalp hair, e.g., eyebrow, eyelash, body hair. * For CLP patients, Patients whose LP is a predominantly bullous variant. * For NSV patients, Participants who have no pigmented hair within any of the vitiligo areas on the face. Note: Other protocol defined Inclusion/Exclusion criteria may apply. ``` ## Arms - **Part A: Single Ascending Doses (SAD) of BG-A3004** (EXPERIMENTAL) — Sequential cohorts of increasing dose levels of BG-A3004 will be evaluated after a single dose in healthy participants. - **Part B: Multiple Ascending Doses (MAD) of BG-A3004** (EXPERIMENTAL) — Sequential cohorts of increasing dose levels of BG-A3004 will be evaluated after multiple doses in participants with immune-mediated skin diseases. - **SAD Placebo** (PLACEBO_COMPARATOR) — Sequential cohorts of healthy participants will receive a single dose of matching placebo. - **MAD Placebo** (PLACEBO_COMPARATOR) — Sequential cohorts of participants with immune-mediated skin diseases will receive multiple doses of matching placebo. ## Interventions - **BG-A3004** (BIOLOGICAL) — Administered subcutaneously - **Placebo** (BIOLOGICAL) — Administered subcutaneously ## Primary Outcomes - **Part A (SAD) and Part B (MAD): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)** _(time frame: up to 24 weeks for Part A and 36 weeks for Part B)_ — Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant abnormalities from laboratory tests, vital signs and electrocardiogram results ## Secondary Outcomes - **Part A (SAD) and Part B (MAD): Maximum observed serum concentration of BG-3004 (Cmax)** _(time frame: up to 24 weeks for Part A and 36 weeks for Part B)_ - **Part A (SAD) and Part B (MAD): Area under the curve (AUC) of BG-3004** _(time frame: up to 24 weeks for Part A and 36 weeks for Part B)_ - **Part A (SAD) and Part B (MAD): Half-life of BG-3004 (t1/2)** _(time frame: up to 24 weeks for Part A and 36 weeks for Part B)_ - **Part A (SAD) and Part B (MAD): Number of Participants with Antidrug Antibodies (ADAs) against BG-A3004** _(time frame: up to 24 weeks for Part A and 36 weeks for Part B)_ - **Part B (MAD): Trough concentration (Ctrough) of BG-3004** _(time frame: up to 36 weeks)_ ## Locations (1) - Peking University First Hospital, Beijing, Beijing Municipality, China — _RECRUITING_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.peking university first hospital|beijing|beijing municipality|china` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT07412691.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT07412691* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*